Skip to main content

Javier Hernandez Losa

Institutions of which they are part

Predoctoral researcher
Translational Molecular Pathology
Vall Hebron Institut de Recerca

Research lines

Role of HER3 expression in carcinogenesis of endometrial and breast tumors. Search for new predictive markers to anti-HER treatments.

The cell signaling pathways downstream of epidermal growth factor receptor family members is tightly regulated in normal epithelial cells, and its alteration induce different cell processes (cell proliferation, cell growth, etc...) which triggers in cellular transformation. Within this family receptors, HER1/EGFR and HER2/neu are the best known, being subject to interest other family members like HER3. The aim of the study is establish de role of HER3 protein expression by Immunohistochemistry in endometrial and breast tumors, and establish any association with clinic-pathological parameters. Furthermore, we would like to know the implication of HER3 in the resistance mechanisms to anti-HER treatment agents.

IP: Javier Hernandez Losa

Projects

Estudio de validación para el uso del anticuerpo ROS1 de Roche para la detección de translocaciones/reordenamientos de ROS1 en cáncer de pulmón mediante Inmunohistoquímica.

IP: Javier Hernandez Losa
Collaborators: -
Funding agency:
Funding:
Reference: PR(AG)291/2019
Duration: -

New biomarkers based on liquid biopsy and Artificial Intelligence for predicting risk of relapse in early stage of Colorrectal tumors.

IP: Javier Hernandez Losa
Collaborators: -
Funding agency:
Funding:
Reference: PR(AG)211/2019
Duration: -

Nueva tecnología para la detección de mutaciones puntuales en el oncogen BRAF a partir de sangre periférica y su validación en muestras tisulares/Tumorales

IP: Javier Hernandez Losa
Collaborators: -
Funding agency:
Funding:
Reference: PR(AG)13/2016
Duration: -

Estudio del análisis mutacional del gen EGFR en muestras de ADN circulante de pacientes con carcinoma de pulmón metastasico, como factor predictivo de respuesta a tratamientos dirigidos frente a dicho receptor.

IP: Javier Hernandez Losa
Collaborators: -
Funding agency:
Funding:
Reference: PR(AG)180/2015
Duration: -

Related news

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

The international study incorporates new magnetic resonance markers to increase sensitivity in the diagnosis of this disease.

The drug EB1 is able to block resistance pathways to standard cancer treatments and could increase the efficacy of chemotherapy or immunotherapy.

Related professionals

María Viñas I Casas

María Viñas I Casas

Predoctoral researcher
Translational Molecular Pathology
Read more
Teresa Moline Marimon

Teresa Moline Marimon

Research technician
Translational Molecular Pathology
Read more
Josep Castellví Vives

Josep Castellví Vives

Translational Molecular Pathology
Read more
Trond Aasen

Trond Aasen

Senior researcher
Translational Molecular Pathology
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.